Background/Aims: The objectives of this study were to evaluate the impact of the neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) on overall survival (OS) and to explore the value of changes in the NLR and PLR with treatment as a response indicator. Methods: A total of 934 patients were eligible for retrospective analysis between 2008 and 2014. The pretreatment and post-treatment PLR and NLR in all patients were calculated based on complete blood counts. Univariate and multivariate Cox regression analyses were performed to determine the associations of the PLR and NLR with OS. Results: The pretreatment NLR and PLR were correlated with different disease status and response to chemotherapy. Patients with lower NLR and PLR had a significantly better complete response (CR) rate to chemotherapy versus those with a higher NLR and PLR (p<0.001). The NLR and PLR were sustained in patients who obtained a CR compared with moderate or poor response patients. The lower NLR of pretreatment was independently associated with a favourable prognosis in whole patients with lung cancer (HR: 0.69, 95% CI, 0.55-0.85, p<0.001). In the patients under control after chemotherapy, the NLR of post-chemotherapy had a greater impact on survival, and the low NLR level maintained during chemotherapy was identified a predictor for favourable survival. PLR was not an independent prognostic indicator in the whole cohort or any subgroups. Conclusion: Our results suggested that NLR was well-connected with outcomes and response to chemotherapy in patients with lung cancer. As a response indicator, NLR may predict benefit from chemotherapy and improve patient selection.
The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer
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Introduction
Lung cancer is one of the most common tumours in the world, and its mortality accounts for 28% in males and 26% in females, ranking first in all cancers [1] . The main treatments for lung cancer are surgery and chemotherapy [2] . Although the treatments in lung cancer have made great progress, more effective treatment strategies must consider patient selection and evaluate the prognosis of patients with lung cancer.
Previous studies showed that cancer-related inflammation has been recognized as one of the markers of cancer with an essential role in the modulation of the tumour microenvironment [3, 4] . Inflammation may play an important role in the tumour genesis process and progression by promoting cancer cell proliferation and survival, angiogenesis, and tumour metastasis, as well as impacting tumour response to systemic therapies [5] . Lymphocytes, which have been thought to play an essential role in cancer immune surveillance, are hypothesized to suppress tumour maturation [6] . In addition, the NLR and PLR are easily measured and repeatable markers, which may provide a simple and cheaper avenue for cancer-related inflammation. The imbalances in the ratio of NLR and PLR may provide insight into understanding tumour progression and prognosis in individuals with cancer [7] . These ratios have shown prognostic relevance across a large variety of tumour types [7] [8] [9] [10] [11] [12] . In lung cancer, a number of retrospective studies have estimated the prognostic significance of baseline NLR and PLR [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] .
However, those studies typically focused on specific types or specific populations with lung cancer. There are few studies evaluating the roles of the NLR and PLR in whole lung cancer cohorts with different subtypes and treatments. The prognostic value of different treatments and the association with response to treatment remain unclear.
The current study aimed to assess the prognostic roles of the NLR and PLR in patients with lung cancer during different treatment status. We also analysed the predictive value of pre/post-treatment NLRs and PLRs for response to chemotherapy.
Materials and Methods

Participants
Patients included in this dataset were hospitalized between January 2008 and Dec 2014. The inclusion criteria included the following: 1) diagnosed lung cancer by biopsy, and 2) data about complete blood count, blood chemistries and other inflammatory factors before and after different treatments. This study was approved by the Ethical Committee of West China Hospital of Sichuan University. All patients signed written informed consent before entering the study.
Data collections and follow up
Data were collected retrospectively from individual medical case notes, electronic patient records and pathology reports, including age, gender, histological subtype, stage, smoking status and therapy. Stage was determined according to the American Joint Committee on Cancer Staging System (AJCC), 7
th Edition [23] . The NLR was defined as the absolute neutrophil count divided by the absolute lymphocyte count, and the PLR referred to the absolute platelet count divided by the absolute lymphocyte count. Values of the pretreatment NLR and PLR were measured as the baseline values at the initial diagnosis before treatment. The post-treatment NLR and PLR were recorded within 7 days after the first cycles of chemotherapy. All the responses to chemotherapy were evaluated according to Response Evaluation Criteria in Solid Tumours, which was a commonly accepted standard to evaluate patient response from a certain treatment [24] . Survival status was determined from the date of last follow-up in Dec 2014. The overall survival time was defined as the time from the confirmed diagnosis of lung cancer to the date of death or to the date of last follow-up for patients who had not died before the censor date. Follow-up was done every 3 months by telephone. The contents of following up included tumour progression, recurrence, metastasis and survival days.
Statistical methods
Continuous data were presented as the mean ± standard deviation. Categorical data were described by the frequency and percentage. Student's t test or one-way ANOVA (Analysis of Variance) were used for continuous variables, and Fisher's exact test or χ2 test was used for comparisons of categorical data separately. SNK was used for multiple samples. ROC curve analysis was carried out to assess the prognostic ability of the PLR and NLR. The optimal cutoff values were identified as the values that maximize the You den index (sensitivity + specificity -1) (Fig 8) [25] . The cutoff values for the NLR and PLR were 3.0 and 160, respectively. Survival curves were estimated with the Kaplan-Meier method. The associations of the NLR and PLR with survival were evaluated in univariable and multivariable Cox regression models. In the multivariable model, all variables with a statistically significant univariate association were included. HRs and 95% CIs were provided for univariable and multivariable Cox regression models. A Cox proportional hazards model was fitted to all individual prognostic variables to determine their independent effect. Analyses were performed in SPSS 21.0 software.
Results
Population characteristics
The clinical characteristics of the population are summarized in Table 1 Table 2 ). The values of the NLR and PLR for both pretreatment and post-chemotherapy in the CR-group were reduced compared with patients with a moderate or poor response (all p<0.05, Table 3 ). The NLR and PLR were sustained in patients who obtained a complete response after two or three cycles of chemotherapy (p>0.05); in patients with a moderate or poor response, the post-chemotherapy NLR and PLR were dramatically increased compared with pretreatment (all p<0.001, Fig 2) . We also did some extra analysis of the current data and provided these result. As for histology, the patients with adenocarcinoma (AC) showed worse OS in high-NLR group at diagnosis ( Fig  4B) . In addition, the patients with higher NLR in small cell lung cancer (SCLC) and AC showed worse OS compared with patients with lower ones after one cycle of chemotherapy ( Fig  4E, Fig. 4F ). For patients receiving surgery, the NLR and PLR of pretreatment were not associated with a prognosis, although patients with a higher NLR and PLR of pretreatment had trends towards poor survival after 30 months (Fig 5) .
We divided patients receiving chemotherapy into subgroups according to response. In patients with disease control (CR+PR+SD), age, stage, surgery, pretreatment NLR and PLR and post-chemotherapy NLR were significantly correlated with survival in the univariate analysis (Table  5) . After adjustment for these factors, only a lower post-chemotherapy NLR still conferred a favourable prognosis in the multivariate analysis (Fig 6, Table 5 ). However, the pretreatment NLR showed no significant difference in these patients. These results indicated that the post-chemotherapy NLR had a greater impact on prognosis than the pretreatment NLR in patients who had disease control after initial chemotherapy.
A lower post-chemotherapy NLR had a trend towards an association with response to initial chemotherapy in the multivariate Patients receiving chemotherapy were divided into four groups, including maintained a low NLR, maintained a high NLR, increased NLR and decreased NLR groups. The analysis revealed that patients who maintained a low NLR had the best survival (median, 56 months), whereas patients with an increased NLR had the worst OS, with a median of 24 months. With adjustments for age, stage and pretreatment PLR, a dynamic change of the NLR during chemotherapy remained an independent predictor of overall survival (HR: 0.196, 95% CI, 0.064-0.602, p=0.004, Fig 7) . The changes in the PLR did not show a significant difference; even patients with an increased PLR had the shortest median survival time (data not shown).
Discussion
In our study, we investigated the prognostic effect of the NLR and PLR on lung cancer by a retrospective analysis of 934 patients with lung cancer. We found that the NLR and PLR were correlated with different disease status and responses to chemotherapy. A lower pretreatment NLR was independently associated with a favourable prognosis in all patients with lung cancer. In the patients with disease control after chemotherapy, a maintained low NLR during chemotherapy was identified as a predictor for favourable survival. The findings suggested that a lower NLR at diagnosis might predict a benefit from chemotherapy among all patients with lung cancer. Although the elevation of 
the pretreatment PLR was also associated with the prognosis in the univariate survival analysis, the multivariate Cox analysis showed that the PLR was not an independent prognostic indicator in the entire cohort or in any subgroups.
It is increasingly recognized that the host systemic inflammatory response plays a critical role in the development and progression of many cancers [26, 27] . An elevated NLR conferred adverse survival in gastrointestinal cancer, pancreatic cancer, breast cancer, bladder cancer and other cancers [7, 9, 28, 29] . A recent meta-analysis of 40599 patients with solid tumours showed that an NLR greater than 4.00 was associated with a substantial increase in the risk for all-cause mortality (HR: 1.81, 95% CI: 1.67-1.97) [8] . Previous studies also demonstrated that the PLR was a prognostic factor in lung cancer. A meta-analysis including 3430 patients proved that an elevated PLR predicted poor OS and poor disease-free survival and progression-free survival in non-small cell lung cancer [30] . The prognostic value of the NLR and PLR in patients with lung cancer appears to have been established by our study and previous studies [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . However, the cutoff value and prognostic effect of the NLR and PLR remain controversial. It has been reported that the optimal cutoff value for prognostic indicators could be better selected by validating previously established values from other studies. Herein, we analysed the optimal cutoff by ROC curve analysis. Based on our findings, a cutoff value of 3.0 for the NLR and 160 for the PLR were determined to distinguish between patients with a higher risk of adverse outcomes and patients with a lower risk. Furthermore, we analysed the association of the NLR and PLR with prognosis according to different cofounders. Our study confirmed the previous conclusion that the NLR is an independent prognostic factor and the PLR has little influence on prognosis after adjustments for other confounders [17, 21, 22] .
The mechanism by which the NLR and PLR may impact prognosis remains unclear. The peripheral NLRs are thought to be proxies of the ongoing inflammatory process in the tumour microenvironment [7] . Several studies demonstrated that neutrophils and platelets contribute to pro-tumour activities in vivo, including enhanced angiogenesis, which promote tumour cell proliferation and the metastatic potential of tumour cells [31] [32] [33] . Meanwhile, lymphocytes have been thought to have an essential role in cancer immune surveillance and are hypothesized to suppress tumour maturation [6] . It is therefore biologically plausible that imbalances in the ratio of the peripheral neutrophils/platelets to lymphocytes may provide insight into understanding tumour progression and prognosis in individuals with cancer [7] .
Systemic inflammation in patients with malignancy is considered to reflect the cytokine profile produced both by the tumour and as a component of the host response to the tumour [34] . Increased levels of systemic inflammation have been shown to correlate with worse survival and a poor response to treatment in a number of solid organ tumours [35, 36] . As our findings showed, patients with a lower NLR had significantly better chemotherapy response versus those with a higher NLR. Both pretreatment and post-chemotherapy NLRs were closely associated with a poor response to chemotherapy. Similarly, a recently reported large retrospective series found that patients with an NLR<3 had significantly better tumourcontrol among patients receiving first line platinum with gemcitabine in advanced biliary tract cancer. Additionally, the post-chemotherapy NLR has a greater impact on the prognosis of patients under control in our study. The level of the NLR changed with the disease status and treatment strategies. Patients who maintained a low NLR during chemotherapy had the most favourable prognosis in patients under control, whereas patients with increased NLR had the shortest survival. The findings suggested that a maintained low level of NLR could be a surrogate for predicting the response to chemotherapy. Chua et al [37] . investigated a total of 162 patients with metastatic colorectal cancer who received palliative chemotherapy and reported that patients with pretreatment NLR values of >5 that decreased to ≤5 before the second chemotherapy cycle showed a significantly longer progression-free survival and a trend towards longer OS compared with patients with a persistent NLR of >5. Data in patients with oesophageal and biliary cancer have also suggested an association between the NLR and response to cisplatin-based chemotherapy [38, 39] . These results indicated that the NLR was predictive for the prognosis and response to chemotherapy regardless of tumour origin. The potential mechanism could be explained by the fact that the inflammation also affects the efficacy of chemotherapy drugs. Our current study found that the pretreatment NLR and PLR were not correlated with survival in patients receiving surgery. These results are different from a previous study that demonstrated that the NLR is a prognostic biomarker in patients with early stage NSCLC undergoing surgery [13] . The difference could be because our study enrolled a larger population in the real world, including different subtypes of lung cancer and a larger proportion of patients with advanced disease. These differences may account for the different results. Unlike Kang et al [22] ., we observed that the NLR and PLR level were increased dramatically after one cycle of chemotherapy, as well as before and after surgery. The distinction may be caused by different definitions of pre and after treatment of NLR and PLR.
Our research was conducted on a relatively large number of participants and confirmed the results of previous studies that showed an association between the NLR and PLR and lung cancer. We investigated the roles of the NLR and PLR at the time of pretreatment and post-treatment in patients with lung cancer. We found that the dynamic change of NLR during chemotherapy could predict the response to chemotherapy. A major advantage of our research is that detailed information on tumour characteristics and treatment were recorded, which allowed for extensive confounder adjustment. In addition, our research was the first to include all other subtypes of lung cancer in the assessment of the prognostic significance of the NLR and PLR.
There are some limitations in our research. As a retrospective study, there are several limitations inherent to the design, including the retrospective data collection. Furthermore, there are several confounding factors, such as inflammatory conditions and steroid treatments [17, 22] . Moreover, the prognostic value of the NLR was found in many types of tumours, indicating that the NLR might not be a tumour-specific marker.
Conclusion
Our results suggested that the NLR showed a strong association with outcome, and its dynamic change may predict a benefit from chemotherapy in a retrospective analysis. These inflammation markers could be used as response indicators for different treatments and may improve patient selection. The NLR may be readily available in clinical practice as prospective stratification criteria in estimating response and assisting clinicians in evaluating patients' overall prognosis.
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